Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2018 Jan 30;27(6):570–580. doi: 10.1002/pds.4389

Table 5.

Comparison with literature effect sizes

Study Population Sample Timeframe Statin Effect estimate (g/m2)
Cohort42 Hyperlipidemia/essential hypertension 60 6 m Pravastatin 10 mg −16
Cohort6 Hypertension/LVH (elderly) 220 12 m Pitavastatin 1–2 mg −6
RCT7 LVH/essential hypertension 41 12 m Simvastatin 10 mg −21
RCT55 Essential hypertension 39 12 m Fluvastatin 20 mg −1
RCT56 Hypertension/LVH 142 6 m Rosuvastatin 20 mg 2
RCT54 Hypertension/high BMI 368 24 m Fluvastatin 40 mg −11*
RCT53 Hypercholesterolemia 50 6 m Pravastatin 10/20 mg −14
This study No CVD, require statins 2389 120 m Statins −2

The majority of these studies were not designed to detect differences between statins and placebo for indexed LVM. The estimates are derived and presented to inform a comparison of the magnitude of the effect.

*

This value is estimated from the change in grams. It assumes BSA remains constant and uses DuBois’ formula to calculate BSA from BMI, weight, and height.